IceCure (NASDAQ: ICCM) VP now holds 106K shares and RSUs

Rhea-AI Filing Summary

Tel-Tzure Tlalit Bussi reported acquisition or exercise transactions in this Form 4 filing.

IceCure Medical Ltd. reported that officer Tel-Tzure Tlalit Bussi, VP, BD & Global Marketing, received a grant of 101,483 restricted share units (RSUs) on August 14, 2026. The RSUs vest over time: 25% on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25% thereafter. Following this award, Bussi’s directly held equity position, including existing ordinary shares and multiple prior RSU grants with similar quarterly vesting structures, is reported at 106,518 ordinary shares/RSUs. Except for the 25% tranche of RSUs granted July 2, 2024 that vested on July 29, 2026, all referenced RSUs remain unvested as of August 13, 2026. The holdings also reflect IceCure’s 1-for-30 reverse share split.

Insider Trade Summary

Net Buyer: 101,483 shares

Net Buy 1 txn

Insider Tel-Tzure Tlalit Bussi

Role VP, BD & Global Marketing

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1	101,483	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 106,518 shares (Direct)

Footnotes (1)

1. F1. Represents (i) 101,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 653 ordinary shares, (iii) 2,273 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iv) 1,733 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (v) 1,029 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings in clauses (ii) through (v) have been adjusted to reflect the Issuer's 1-for-30 reverse share split.

Key Figures

RSUs granted: 101,483 RSUs Post-transaction holdings: 106,518 shares/RSUs Grant price per share: $0.0000 per share +5 more

8 metrics

RSUs granted 101,483 RSUs Restricted share units granted to Tel-Tzure Tlalit Bussi on August 14, 2026

Post-transaction holdings 106,518 shares/RSUs Total direct equity position following the August 14, 2026 grant

Grant price per share $0.0000 per share Reported acquisition price for the RSU-related ordinary shares

Initial vesting portion 25% Portion of each RSU grant that vests on the first specified vesting date

Subsequent vesting portion 75% Remaining RSUs vesting after the initial 25% tranche

Quarterly vesting rate 6.25% per quarter Rate at which the remaining 75% of each RSU grant vests

Reverse share split ratio 1-for-30 Reverse share split applied to adjust reported holdings

Ordinary shares held 653 shares Portion of Bussi’s position represented by directly held ordinary shares

Key Terms

restricted share units, reverse share split, vest, ordinary shares

4 terms

restricted share units financial

"Represents (i) 101,483 restricted share units ("RSUs") granted on August 14, 2026"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

reverse share split financial

"holdings in clauses (ii) through (v) have been adjusted to reflect the Issuer's 1-for-30 reverse share split"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

vest financial

"25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

ordinary shares financial

"Represents (i) 101,483 restricted share units ("RSUs") ... (ii) 653 ordinary shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

What equity award did Tel-Tzure Tlalit Bussi receive from ICCM on August 14, 2026?

Tel-Tzure Tlalit Bussi received a grant of 101,483 RSUs on August 14, 2026. This award vests 25% on August 11, 2027, with the remaining 75% in twelve quarterly 6.25% installments thereafter.

How many ICCM shares and RSUs does Tel-Tzure Tlalit Bussi hold after this transaction?

After the reported grant, Bussi’s direct equity position is 106,518 ordinary shares/RSUs. This figure includes the new 101,483 RSUs, 653 ordinary shares, and several prior RSU grants with scheduled vesting.

What is the vesting schedule for the 101,483 ICCM RSUs granted to Tel-Tzure Tlalit Bussi?

The 101,483 RSUs vest 25% on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25% each following that date, subject to the underlying terms.

Which earlier ICCM RSU grants to Tel-Tzure Tlalit Bussi are referenced and how do they vest?

Referenced RSU grants include 2,273 (July 2, 2024), 1,733 (November 5, 2025), and 1,029 (March 16, 2026). Each vests 25% on a specified first vesting date, with the remaining 75% in equal 6.25% quarterly installments.

How did IceCure Medical’s 1-for-30 reverse share split affect Tel-Tzure Tlalit Bussi’s reported holdings?

Bussi’s reported holdings have been adjusted to reflect IceCure Medical’s 1-for-30 reverse share split. The footnote states that the quantities in several holding components were changed to account for this reverse split.

Are most of Tel-Tzure Tlalit Bussi’s ICCM RSUs vested or unvested as of August 13, 2026?

As of August 13, 2026, all referenced RSUs remain unvested except for the 25% tranche of the RSUs granted on July 2, 2024, which vested on July 29, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 08:17 AM Accepted by SEC EDGAR 08/17/2026 - 08:17 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tel-Tzure Tlalit Bussi

(Last) (First) (Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA 3079504

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, BD & Global Marketing

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/14/2026		A		101,483	A	$0	106,518(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents (i) 101,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 653 ordinary shares, (iii) 2,273 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iv) 1,733 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (v) 1,029 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings in clauses (ii) through (v) have been adjusted to reflect the Issuer's 1-for-30 reverse share split.

	/s/ Tlalit Bussi Tel-Tzure	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)